drugset / Trial / NCT00564057

Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

NCT00564057

Phase 4 Unknown 30 enrolled University of Insubria
RandomizedParallel-groupDouble-blindTreatment

Summary

Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.

Timeline

Start
2007-09
Primary completion
Completion
2009-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan Unknown 8 mg Oral
Subject Candesartan Unknown 16 mg Oral
Comparator Lercanidipine Small molecule 10 mg Oral
Comparator Lercanidipine Small molecule 20 mg Oral